Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · Real-Time Price · USD
6.22
-0.17 (-2.66%)
Jun 12, 2025, 11:53 AM - Market open
Verve Therapeutics Employees
Verve Therapeutics had 274 employees as of December 31, 2024. The number of employees increased by 19 or 7.45% compared to the previous year.
Employees
274
Change (1Y)
19
Growth (1Y)
7.45%
Revenue / Employee
$217,566
Profits / Employee
-$660,606
Market Cap
554.47M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 274 | 19 | 7.45% |
| Dec 31, 2023 | 255 | 51 | 25.00% |
| Dec 31, 2022 | 204 | 91 | 80.53% |
| Dec 31, 2021 | 113 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
VERV News
- 9 days ago - Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Verve Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 23 days ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 4 weeks ago - Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy' - Seeking Alpha
- 2 months ago - Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose - Benzinga
- 2 months ago - Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 - GlobeNewsWire
- 2 months ago - Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 - GlobeNewsWire